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1 
MICROBE DETECTION VIA HYBRIDIZING 
MAGNETIC RELAXATION NANOSENSORS 
The Sequence Listing submitted on Nov. 20, 2014 as a text 
file named "26150_0051 U2_Sequence_Listing.txt," created 
on Nov. 20, 2014, and having a size of741 bytes is hereby 
incorporated by reference pursuant to 37 C.F.R. § 1.52( e )(5). 
BACKGROUND 
Pathogenesis caused by intracellular pathogens, such as 
Mycobacterium tuberculosis among others, relies on the sur-
vival of the microorganism within host cells, such as mac-
rophages and dendritic cells. This mode of infection with or 
without clinical symptomology hampers bacterial detection, 
preventing correct diagnosis. Consequently, the physician 
cannot proceed to the assignment of an appropriate treatment 
course, delaying the clearance of the pathogen from the body. 
Serological immunoassays cannot effectively detect intracel-
lular pathogens in biological fluids (e.g. blood, lymphatic 
fluid) as the microorganism is hidden away within the 
immune cells. For this reason, isolation of the infected cells 
and extraction of their DNA, followed by detection of specific 
bacterial genomic markers via Polymerase Chain Reaction 
(PCR), is needed to facilitate identification of the pathogen. 
Although highly specific and sensitive, PCR methods are 
generally laborious, time-consuming and typically require 
homogeneous and pure DNA samples [1]. Evidently, com-
plex biological samples, such as biopsies and blood, have to 
be thoroughly processed in multistep elaborate protocols to 
obtain pure DNA samples, significantly increasing the final 
readout time, and affecting the overall DNA yield. An alter-
native way to detect intracellular pathogens, particularly 
when they are in low numbers, is by isolating the infected 
leukocytes from the blood and expanding the number of 
viable bacteria via culturing methods before PCR analysis. 
Although very effective, bacterial culturing methods require a 
significant amount of time, such as in the case of slow-grow-
ing intracellular pathogens that have to be cultivated for even 
weeks, assuming that there is an adequate amount of viable 
pathogens in the clinical sample. Another drawback of cul-
turing methods is that some pathogens do not grow effectively 
in culture, either because of the nature of the pathogen itself 
2 
changes in the sample's magnetic resonance signal (specifi-
cally the water proton relaxation time; T2) occur that corre-
late with the target concentration in solution. By measuring 
the changes in T2 relaxation times upon target interaction and 
correlating the intensity of the change with the target concen-
tration, one can develop a sensitive detection method, there-
fore the acronym of magnetic relaxation nano sensors (MRS). 
In contrast to other methods that utilize magnetic nanopar-
ticles as labels and directly measure an intrinsic physical 
10 property, such as a magnetic field [13], [14], or a chemical 
property [6], the MRS method relies on the effect that the 
nanoparticle' s induced magnetic field exerts on the hundreds 
of thousands of water molecules surrounding the nanopar-
ticle. This effect results in an amplification of the signal, 
15 allowing for sensitive detection even in turbid and minimally 
processed samples, without the need of further amplification, 
which is critical for assays such as PCR and ELISA. Hence, 
MRS-based assays can be more affordable than traditional 
assays, since they use a single reagent that can be easily 
20 produced in large quantities, and a single-step that avoids 
time- and labor-consuming procedures. Additionally, MRS 
can detect their targets at various point-of-care settings, since 
the nanosensors are stable at ambient conditions and utilize 
deployable instrumentation. Recently reported is a unique 
25 MRS nanoparticle-target interaction that resulted in rapid T2 
increases upon target binding [12]. This unique nanoparticle-
target interaction is different from other MRS-based meth-
ods, because clustering of the nanoparticles is not required to 
achieve detection. In contrast, binding of MRS to the target 
30 caused fast, target-concentration-dependent increases in T2. 
Kinetic studies also revealed that the binding of MRS was 
faster and more sensitive than the MRS clustering, while 
achieving lower detection thresholds. In addition, nanopar-
ticle valency-the amount of a targeting ligand on the surface 
35 of the nanoparticle-plays a role in the magnetic relaxation 
response. Nanoparticle valency controls the trend of the 
change in the spin-spin relaxation time (flT2). Specifically, it 
has been found that low valency results in decreases in the 
fl T2 as the target concentration increases, while at high 
40 valency conditions the fl T2 increases as the target concentra-
tion increases. 
SUMMARY 
or the presence of biological interferences present in the 
clinical sample that prevent growth in culture. Because of 45 
these hurdles, new technologies that can detect the presence 
Disclosed herein are materials and methods that take into 
consideration the faster detection kinetics of MRS binding-
based detection assays and the higher sensitivity of the MRS 
low-valency nanoparticle system. In one embodiment, dis-
closed is a newly developed nanosensor, hybridizing MRS 
(hMRS), that switches (increases) the sample's water proton 
relaxation times (T2) upon binding to a unique genomic 
of a pathogen in human clinical samples are urgently needed. 
marker (e.g. microbial). According to one example, the 
hMRSs were designed to bind to a specific genomic marker in 
Mycobacterium avium spp. paratuberculosis (MAP); an 
intracellular pathogen known to cause Johne's disease in 
cattle [15] and has been also implicated in the cause of 
Crohn's disease in humans [16]. Furthermore, acknowledg-
ing the limitations of PCR in detecting nucleic acid biomar-
kers of intracellular pathogens in clinical samples, the hMRS 
It has been predicted that nanotechnology will have a major 
impact in medicine, agriculture and biotechnology among 
other fields [2], [3], [4], [5], [6], [7], [8], [9], [10]. Innovative 50 
technologies that take advantage of the unique size-depen-
dent electronic, magnetic and luminescence properties that 
some nanomaterials exhibit when they specifically interact 
with a biological marker have been developed for faster and 
more accurate sensing of various pathogens [2], [3], [4], [5]. 55 
However, the translation of these technologies to the clinical 
diagnosis of an infectious disease and how it relates to the 
presence of the pathogen in clinical samples has been limited. 
The slow clinical translation of some of these nanotechnolo-
gies has been partly due to their poor performance in crude or 
minimally processed clinical samples. Among the most 
promising nanomaterials are magnetic relaxation nanosen-
sors (MRS). These magnetic nanosensors are composed of a 
polymer-coated iron oxide nanoparticle onto which affinity 
ligands are conjugated to facilitate binding and magnetic 
detection of a particular target [11], [12]. Upon specific bind-
ing of a target to ligands on the magnetic nanoparticle, 
60 performance in detecting MAP was examined in human 
peripheral blood samples of Crohn' s disease patients as well 
as animal tissues with Johne's disease. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
65 by one of ordinary skill in the art to which this invention 
belongs. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
US 9, 109,249 B2 
3 
testing of the present invention, suitable methods and mate-
rials are described below. All publications, patent applica-
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety. In case of conflict, 
the present specification, including definitions, will control. 5 
In addition, the materials, methods, and examples are illus-
trative only and not intended to be limiting. 
BRIEF DESCRIPTION OF DRAWINGS 
4 
FIG. 6 (a) Blood samples from a second population (Co-
hort 2, n=26) were screened for the presence of the MAP 
IS900 genomic element with hMRS, direct nPCR and cul-
ture-based nPCR after 12-week cultivation. The receiver 
operating characteristic (ROC) curve indicated that the 
hMRS, can better differentiate between symptomatic 
(Crohn's) and asymptomatic (healthy) states than the two 
gold standard methods. (b) Two-proportion z-test confirmed 
hMRS as a better clinical diagnostic utility than the PCR-
10 based methods. 
FIG. 7 Kinetics for MAP's IS900 genomic marker detec-
tion with hMRS. After heating the samples to facilitate DNA 
stand separation and hMRS hybridization, the changes in the 
T 2 magnetic resonance signal were recorded over time, with 
FIG. 1 Design of a nanoparticle-based assay for the iden-
tification of genomic markers of the intracellular pathogen 
Mycobacterium avium spp. paratuberculosis (MAP). (a) Iso-
lation of MAP requires collection of infected white bloods 
cells from blood samples via centrifugation. For direct nPCR 
analysis, DNA directly isolated from white blood cells is 
purified in multiple steps prior to amplification and detection 
15 marked changes occurring within less than an hour 
(Means± SE). 
FIG. 8 Nested PCR (nPCR) cannot quantify crude MAP 
DNA. -Ctr!: negative control (dH20) of the first nPCR 
round, -Ctr!: negative control (dH20) of the second nPCR 
20 round, TE: TE buffer, +Ctr!: two controls of pure extracted 
MAP DNA. 
by gel electrophoresis. Meanwhile, culture-based nPCR 
requires the growth of MAP in specialized liquid media for 12 
weeks, followed by DNA isolation before nPCR. Hybridizing 
magnetic relaxation sensors (hMRS) can detect MAP DNA in 
minimally processed blood samples via changes in magnetic 
signal (fl T2) in 1 hour, as opposed to 24 hours for direct nPCR 
and 12 weeks for culture nPCR. (b) Preparation of MAP DNA 
for hMRS. Heating ofinfected leucocytes facilities rupture of 25 
the cell membrane releasing MAP DNA. Further heating and 
cooling steps facilitates the annealing and binding of a MAP 
specific hMRS, resulting in an increase in the T 2 water relax-
ation time. 
FIG. 2 Specificity and sensitivity of the IS900-detecting 30 
hMRS. (a) hMRS specifically bind to MAP DNA and not 
DNA from other mycobacteria or common pathogens 
([hMRS]=3 µg Fe/µL). hMRS facilitates the fast and quanti-
tative detection of MAP DNA in pure (b) and crude ( c) 
samples within 30 minutes. Comparison of the sensitivity of 35 
the hMRS and nested PCR (nPCR). (d) Within 30 minutes, 
the hMRS detected a single MAP genome copy, translating to 
one bacterium. (e) After its second amplification round (6 
hours), nPCR achieved comparable sensitivity. (Upper gel 
image: first nPCR round (3 hours), lower gel image: second 40 
nPCRround (total two-round time 6 hours), -Ctr!: dH2 0 and 
0: sterile TE buffer). 
FIG. 3 Screening of clinical isolates with hMRS and nPCR. 
Comparison between the magnetic relaxation-mediated 
detection of MAP in clinical isolates using hMRS after crude 45 
DNA extraction and culture-based nPCR. All isolates were 
from blood samples from Crohn' s disease patients, apart from 
GN2' and GNS' that correspond to ilea! biopsies. 
FIG. 4 Comparison between the hMRS genomic detection 
of MAP in clinical isolates and homogenized tissues with the 50 
presence of MAP protein markers using anti-MAP antibodies 
conjugated MRS. (a) hMRS detected MAP genomic tags in 
clinical isolates via changes in the magnetic resonance signal. 
FIG. 9 Genome-copy-based quantification of MAP with 
hMRS and crude extracted DNA. Samples with known 
amounts of crude DNA from cultured MAP were utilized to 
correlate the changes in the T2 signal (fl T2+) and the number 
of bacteria originally present in the sample, using the MAP' s 
genome size as a reference. (Means±SE. SE too small to 
depict in high bacterial levels.) 
DESCRIPTION OF SUPPLEMENTARY TABLES 
Table Sl Spin-spin relaxation times (T2) of crude MAP 
DNA samples. Serial dilutions of crude MAP DNA samples 
have been utilized to assess the sensitivity of the hMRS 
method in minimally processed bacterial cultures. The aver-
ages of each independent experiment are listed and the stud-
ies' mean. 
Table S2 Spin-spin relaxation times (T2) of pure MAP 
DNA samples with known genome copies. Three indepen-
dent experiments were performed on pure DNA samples 
obtained from cultured MAP. Correlation between DNA lev-
els and bacterial populations was achieved by quantifying 
DNA spectrophotometrically and using the MAP genome 
size as a reference. 
Table S3 Demographics of cultured clinical isolates that 
were screened withhMRS andnPCR. (CD: Crohn's disease, 
IBD: inflammatory bowel disease) 
Table S4 Clinical data and hMRS results of Cohort 1 blood 
samples. Samples from Crohn's disease (CD) patients, 
healthy individuals or asymptomatic carriers were analyzed 
by direct nPCR and hMRS. Quantification of the MAP 
genome copies was achieved in positive ( +) samples using a 
training standard curve for crude extracted MAP DNA. 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, 
it is to be understood that this disclosure is not limited to 
particular embodiments described, and as such may, of 
(b) A second preparation of magnetic nano sensors carrying 
polyclonal anti-MAP antibodies ( anti-MAP-pAb) was able to 55 
corroborate the presence of MAP in these clinical isolates by 
the identification of MAP surface epitopes. ( c) hMRS 
detected MAP's IS900 in homogenized tissue from Johne's 
disease cattle. ( d) Corroboration of the presence of MAP in 
the cattle samples using anti-MAP-pAb MRS nanosensors. 
FIG. 5 Detection of Mycobacterium avium spp paratuber-
culosis' genomic marker in clinical samples with hMRS and 
direct nPCR. The hMRS detected MAP's IS900 region in 
minimally processed blood samples (Cohort 1, n=34). Cor-
relation of the hMRS findings was achieved through pure 65 
DNA extraction from white blood cells and direct nPCR. 
60 course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only, and is not intended to be limiting, since 
the scope of the present disclosure will be limited only by the 
Results are means±SE. 
appended claims. 
Where a range of values is provided, it is understood that 
each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 
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the upper and lower limit of that range and any other stated or 
intervening value in that stated range, is encompassed within 
the disclosure. The upper and lower limits of these smaller 
ranges may independently be included in the smaller ranges 
and are also encompassed within the disclosure, subject to 
any specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud-
ing either or both of those included limits are also included in 
the disclosure. 
6 
have the meaning ascribed in U.S. Patent law and the term is 
open-ended, allowing for the presence of more than that 
which is recited so long as basic or novel characteristics of 
that which is recited is not changed by the presence of more 
than that which is recited, but excludes prior art embodi-
ments. 
Bacterial infections are a major global healthcare problem, 
and their detection has to be performed in diverse settings and 
samples preferably with single-instrument-based diagnostic 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this disclosure 
belongs. Although any methods and materials similar or 
equivalent to those described herein can also be used in the 
practice or testing of the present disclosure, the preferred 
methods and materials are now described. 
10 modalities, using sensitive and robust probes. Acknowledg-
ing these concerns, hybridizing magnetic nanosensors 
(hMRS) were used for the detection of the intracellular slow-
growing pathogen Mycobacterium avium spp. paratubercu-
losis (MAP) that resides in peripheral macrophages, through 
All publications and patents cited in this specification are 
herein incorporated by reference as if each individual publi-
cation or patent were specifically and individually indicated 
to be incorporated by reference and are incorporated herein 
by reference to disclose and describe the methods and/or 
materials in connection with which the publications are cited. 
The citation of any publication is for its disclosure prior to the 
filing date and should not be construed as an admission that 
the present disclosure is not entitled to antedate such publi-
cation by virtue of prior disclosure. Further, the dates of 
publication provided could be different from the actual pub-
lication dates that may need to be independently confirmed. 
15 the identification of its unique genomic signature. Clinically 
relevant samples, including tissue and blood, were screened 
with hMRS and gold standard PCR assays. Within less than 
an hour, the hMRS identified MAP-positive samples in a 
library of laboratory cultures, clinical isolates, blood and 
20 homogenized tissues. Comparison of the hMRS with PCR 
methodologies in terms of prediction of disease state revealed 
that the hMRS outperformed the other assays, while being 
significantly faster (1 hour vs 12 weeks). Additionally, using 
a single instrument detection of the intracellular bacterial 
25 target in clinical samples was possible at the genomic and 
epitope levels. There are, therefore, clinical and field uses of 
the hMRS in the multiplexed identification of microbial 
pathogens and other disease-related biomarkers via a single 
instrument in clinical and complex environmental samples, As will be apparent to those of skill in the art upon reading 
this disclosure, each of the individual embodiments described 
and illustrated herein has discrete components and features 
which may be readily separated from or combined with the 
features of any of the other several embodiments without 
departing from the scope or spirit of the present disclosure. 
Any recited method can be carried out in the order of events 35 
recited or in any other order that is logically possible. 
30 for which the use in detecting MAP and its correlation with a 
disease such as diabetes is one example. 
Embodiments of the present disclosure will employ, unless 
otherwise indicated, techniques of medicine, organic chem-
istry, biochemistry, molecular biology, pharmacology, and 
the like, which are within the skill of the art. Such techniques 40 
are explained fully in the literature. 
It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a support" 45 
includes a plurality of supports. In this specification and in the 
claims that follow, reference will be made to a number of 
terms that shall be defined to have the following meanings 
unless a contrary intention is apparent. 
As used herein, the following terms have the meanings 50 
ascribed to them unless specified otherwise. In this disclo-
sure, "comprises," "comprising," "containing" and "having" 
and the like can have the meaning ascribed to them in U.S. 
Patent law and can mean "includes," "including," and the like; 
"consisting essentially of' or "consists essentially" or the 55 
like, when applied to methods and compositions encom-
passed by the present disclosure refers to compositions like 
those disclosed herein, but which may contain additional 
structural groups, composition components or method steps 
(or analogs or derivatives thereof as discussed above). Such 60 
additional structural groups, composition components or 
method steps, etc., however, do not materially affect the basic 
and novel characteristic( s) of the compositions or methods, 
compared to those of the corresponding compositions or 
methods disclosed herein. "Consisting essentially of' or 65 
"consists essentially" or the like, when applied to methods 
and compositions encompassed by the present disclosure 
MAP is found within the white blood cells of infected 
animals with Johne's disease, a form of animal paratubercu-
losis, which is associated with chronic enteritis, reminiscent 
ofCrohn's disease in humans [16]. As early as 1913, Dalziel 
noted the clinical similarities of animal paratuberculosis, 
intestinal tuberculosis and human chronic granulomatous 
enteritis (Crohn's disease) [17]. In humans, Crohn's disease 
is a debilitating chronic inflammatory syndrome of the gas-
trointestinal track and adjacent lymph nodes [17], [18], [19]. 
The detection of MAP in tissues from patients with Crohn's 
disease has been extensively reported. Of particular impor-
tance to our study is the report of the presence of MAP in 
human peripheral blood [20], [21], [22]. In those studies, 
MAP was identified by a culture method followed by PCR 
identification of a MAP genomic marker. The whole process 
took several months to complete, due to the slow growing 
nature of this pathogen. Such a slow detection method not 
only delays the diagnosis, but also slows any potential thera-
peutic intervention [20], [21]. Likewise, difficulties in detect-
ing an intracellular pathogen, such as MAP, hamper studies 
aimed at the investigation of the potential role of MAP in 
Crohn's disease pathology, as well as the pathogen's impact 
on the dairy and beef industries. 
Attracted by MAP's slow growing characteristics, intrac-
ellular residence and clinical and agricultural relevance, 
hMRS was used for the identification of a highly conserved 
MAP genomic element (IS900). This unique DNA insertion 
sequence has been previously used to identify MAP in clini-
cal samples and cultures by PCR, as it has not been found in 
other microorganisms or mycobacteria [23], [24], [25]. 
Detection is primarily achieved through either direct or cul-
ture-based nested PCR (nPCR), which use pure DNA extracts 
from infected leukocytes. Both PCR methods sequentially 
amplify a 398 bp fragment (amplification round 1) and a 298 
bp internal sequence (amplification round 2 ). It was reasoned 
that the binding ofhMRS to IS900 would achieve faster and 
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more sensitive detection of MAP DNA via magnetic relax-
ation in minimally processed clinical samples. Initial studies 
revealed that hMRS can specifically detect MAP's genomic 
marker without showing cross-reactivity with other myco-
bacteria. Furthermore, the presence of MAP in homogenized 
tissues from Johne's disease cattle was achieved at the 
genomic and epitope levels using hMRS and anti-MAP anti-
body-carrying MRS, demonstrating that the MRS technology 
can achieve detection at the genome and organism levels 
using diverse molecular probes. Finally, a library of 60 blood 
samples from Crohn's disease patients and healthy individu-
als was screened with hMRS and nPCR assays. Using mini-
mally processed blood samples, within 60 minutes the hMRS 
were able to detect the intracellular pathogen and better pre-
dict the clinical condition of an individual (healthy vs Crohn' s 
disease) than the nPCR methodologies. Specifically, hMRS 
outperformed the 12-week-long culture-based nPCR in clini-
cal prognosis, as well as the least reliable direct nPCR, which 
are currently used in clinical and research studies. Overall, the 
present disclosure demonstrates for the first time the use and 
validation of a novel translational nanotechnology, where the 
unique water relaxation properties ofiron oxide nanoparticles 
and the dynamics of the nanoparticle/target interaction were 
harnessed to achieve a sensitive genomic biomarker detection 
system for an intracellular pathogen in samples directly 
obtained from human patients. 
As used herein, a "sample" or "test sample" can include, 
but is not limited to, biological material obtained from an 
organism or from components of an organism, food sample, 
or environmental sample (e.g. water sample or any other 
sample from an environmental source believed to contain a 
microorganism). The test sample may be of any biological 
tissue or fluid, for example. In some embodiments, the test 
sample can be a clinical sample derived from a patient. 
Examples oftest samples include, but are not limited to spu-
tum, cerebrospinal fluid, blood, blood fractions such as serum 
and plasma, blood cells, tissue, biopsy samples, urine, peri-
toneal fluid, pleural fluid, amniotic fluid, vaginal swab, skin, 
lymph fluid, synovial fluid, feces, tears, organs, or tumors. A 
test sample can also include recombinant cells, cell compo-
nents, cells grown in vitro, and cell culture constituents 
including, for example, conditioned medium resulting from 
the growth of cells in cell culture medium. 
8 
In a typical example, the hMRS includes a magnetic nano-
particle. The magnetic nanoparticle is typically is comprised 
of metal and/or metal oxide. 
According to another embodiment, provided is a hybridiz-
ing magnetic relaxation nanosensor that includes a magnetic 
nanoparticle associated with a nucleic acid that is configured 
to specifically hybridize to a nucleic acid analyte of interest. 
In a typical example, the nucleic acid analyte of interest is of 
a microorganism. In a specific example, the microorganism is 
10 Mycobacterium avium spp. paratuberculosis. 
Another embodiment disclosed is a method of distinguish-
ing a mycobacterial related bowel condition from a non-
mycobacterial related bowel condition in a patient exhibiting 
symptoms of a bowel condition. In a specific example, the 
15 mycobacterial related bowel condition is inflammatory bowel 
disease (IBD). In an even more specific example, the bowel 
condition is Crohn' s disease. A patient exhibiting symptoms 
of a bowel condition typically will exhibit one or more of the 
following symptoms: abdominal pain, vomiting, diarrhea, 
20 rectal bleeding, severe internal cramps/muscle spasms in the 
region of the pelvis, weight loss and various associated com-
plaints or diseases like arthritis, pyoderma gangrenosum, por-
ridge-like stool, and primary sclerosing cholangitis. 
Typically, a method of distinguishing the conditions 
25 involves (a) subjecting nucleic acid from a sample obtained 
from the patient with at least one hybridizing magnetic relax-
ation nanosensor (hMRS), wherein said hMRS is configured 
to specifically hybridize to a nucleic acid analyte of interest of 
Myca bacterium avium spp. paratuberculosis; and detecting a 
30 change in the magnetic resonance signal from a hMRS 
hybridized to a nucleic acid analyte of interest in the nucleic 
acid from the sample; wherein a change in the magnetic 
resonance signal indicates that the patient has a mycobacte-
rial related bowel condition. Upon determining that the bowel 
35 condition is a mycobacterial related bowel condition, a thera-
peutically effective amount of an antibiotic composition can 
be administered to the patient. Examples of such antibiotics, 
include, but are not limited to, metronidazole, ciprofloxacin, 
rifaximin, rifabutin, clarithromycin, and metronidazole/ 
40 ciprofloxacin combination, vancomycin, azathioprine, inflix-
imab, tobramycin, or combinations of any of the foregoing. 
The term "microorganism" as used herein is intended to 
include a virus, bacteria or fungi organism. 
Hybridizing Magnetic Relaxation Nanosensors (hMRS) 
According to one embodiment, a method of detecting a 45 
nucleic acid analyte of interest in a sample is provided. The 
method includes subjecting nucleic acid from the sample with 
In some embodiments, the hMRS includes a capture probe 
associated with a magnetic responsive particle. Typically, the 
capture probe pertains to a nucleic acid. As used herein with 
respect to a nucleic acid capture probe, "nucleic acid" refers 
to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) 
at least one hybridizing magnetic relaxation nanosensor 
(hMRS), wherein said hMRS is configured to specifically 
hybridize to the nucleic acid analyte of interest. The method 
further includes detecting a change in the magnetic resonance 
signal from a hMRS hybridized to a nucleic acid analyte of 
interest in the nucleic acid from the sample; thereby detecting 
the presence of the nucleic acid analyte of interest in the 
sample. In a specific embodiment, the at least one hMRS 
pertains to a population of hMRS configured to specifically 
hybridize to the nucleic acid analyte of interest. In another 
specific embodiment, nucleic acid is isolated from the sample 
prior to the subjecting step, to obtain isolated nucleic acid. 
Thus, in this specific example, the hMRS is applied to the 
isolated nucleic acid. 
In another specific example, the nucleic acid analyte of 
interest is of a microorganism. In a more specific example, the 
microorganism is a mycobacterium. In an even more specific 
embodiment, the microorganism is a strain of Myca bacterium 
avium spp. paratuberculosis. One specific example of a 
nucleic acid analyte is IS900. 
50 and known analogs, derivatives, or mimetics thereof. A 
nucleic acid capture probe can be oligomeric and include 
oligonucleotides, oligonucleosides, oligonucleotide analogs, 
oligonucleotide mimetics and chimeric combinations of 
these. A nucleic acid capture probe can be single-stranded, 
55 double-stranded, circular, branched, or hairpin and can con-
tain structural elements such as internal or terminal bulges or 
loops. 
In some embodiments, a nucleic acid capture probe can 
have a length of at least, or at least about 5, 6, 7, 8, 9, 10, 11, 
60 12, 13,14, 15, 16, 17, 18,19,20,21,22,23,24,25,26,27,28, 
29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45, 
46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62, 
63,64,65,66,67,68,69,70, 71, 72, 73, 74,75, 76, 77, 78, 79, 
80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96, 
65 97, 98, 99, or 100 nucleobases, or the nucleic acid capture 
probe can have a length within any range bounded by two of 
the above-mentioned lengths. 
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In several embodiments, a nucleic acid capture pro be and a 
nucleic acid analyte of interest bind to form a duplex. Such 
binding may occur through hybridization. As used herein, 
"hybridization" means the pairing of complementary strands 
of a nucleic acid capture probe and a nucleic acid analyte of 
interest. While not limited to a particular mechanism, the 
most common mechanism of pairing involves hydrogen 
bonding, which may be Watson-Crick, Hoogsteen or reversed 
Hoogsteen hydrogen bonding, between complementary 
nucleoside or nucleotide bases (nucleobases) of the strands of 
a nucleic acid capture probe and nucleic acid analyte of inter-
est. 
In some embodiments, a nucleic acid capture probe and 
nucleic acid molecule of interest can hybridize under "strin-
gent conditions," which refer to conditions under which a 
nucleic acid capture probe will hybridize to a nucleic acid 
molecule of interest, but to a minimal number of other 
sequences. A person ofordinary skill in the art will appreciate 
that stringent conditions are sequence-dependent and will 
vary in different circumstances. High stringency conditions 
can be provided, for example, by hybridization in 50% for-
mamide, 5xDenhardt's solution, 5xSSPE, 0.2% SDS at 42° 
C., followed by washing in O.lxSSPE, and 0.1 % SDS at 65° 
C. 
"Complementarity," as used herein, refers to the capacity 
for precise pairing between two nucleobases of a nucleic acid 
capture probe and nucleic acid analyte of interest. For 
example, if a nucleobase at a certain position of a capture 
probe is capable of hydrogen bonding with a nucleobase at a 
certain position of a nucleic acid analyte of interest, then the 
position of hydrogen bonding between the capture probe and 
the nucleic acid analyte of interest is considered to be a 
complementary position. The capture probe and the analyte 
of interest are complementary to each other when a sufficient 
number of complementary positions in each molecule are 
occupied by nucleobases which can hydrogen bond with each 
other. Thus, in some embodiments a nucleic acid capture 
probe and nucleic acid analyte of interest are specifically 
hybridizable and complementary, which indicate a sufficient 
degree of precise pairing or complementarity over a sufficient 
number ofnucleobases such that stable and specific binding 
occurs. 
It will be appreciated that the sequence of a nucleic acid 
capture probe need not be 100% complementary to that of a 
nucleic acid analyte ofinterest to be specifically hybridizable. 
Moreover, a nucleic acid capture probe may hybridize over 
one or more segments such that intervening or adjacent seg-
ments are not involved in the hybridization event (e.g., a loop 
structure, mismatch or hairpin structure). The nucleic acid 
capture probes of several embodiments can comprise at least 
70%, or at least 75%, or at least 80%, or at least 85%, or at 
least 90%, or at least 92%, or at least 95%, or at least 97%, or 
at least 98%, or at least 99% sequence complementarity to a 
region within the nucleic acid sequence of the analyte of 
interest. The degree of complementarity to be specifically 
hybridizable can be selected according to well-known prin-
ciples of hybridization and in accordance with the intended 
analytical procedure. 
In several embodiments, a nucleic acid capture probe can 
comprise one or more oligonucleotide mimetics. The term 
"mimetic" includes oligomeric nucleic acids wherein the 
furanose ring or the furanose ring and the intemucleotide 
linkage are replaced with non-naturally occurring groups. 
In certain embodiments, a nucleic acid capture probe com-
prises a peptide nucleic acid (PNA) oligonucleotide mimetic 
(Nielsen et al., Science, 1991, 254, 1497-1500). PNAs have 
favorable hybridization properties, high biological stability 
10 
and are electrostatically neutral molecules. In PNA oligo-
nucleotide mimetics, the sugar-backbone of an oligonucle-
otide is replaced with an amide containing backbone, in par-
ticular an aminoethylglycine backbone. The nucleobases are 
bound directly or indirectly to aza nitrogen atoms of the 
amide portion of the backbone. Representative U.S. patents 
that teach the preparation of PNA oligomeric compounds 
include U.S. Pat. Nos. 5,539,082; 5,714,331 and 5,719,262. 
PNA compounds can be obtained commercially from 
10 Applied Biosystems (Foster City, Calif., USA). Numerous 
modifications to the basic PNA backbone are known in the art 
and can be used in several embodiments. 
Another class of oligonucleotide mimetic that can be used 
for nucleic acid capture probes in several embodiments is 
15 linked morpholino units (morpholino nucleic acid) having 
heterocyclic bases attached to the morpholino ring. A number 
oflinking groups have been reported that link the morpholino 
monomeric units in a morpholino nucleic acid. Morpholino-
based oligomeric compounds are non-ionic mimetics of oli-
20 gonucleotides which are less likely to form undesired inter-
actions with cellular proteins (Dwaine A. Braasch and David 
R. Corey, Biochemistry, 2002, 41(14), 4503-4510). Themor-
pholino class of oligomeric compounds has been prepared 
with a variety of different linking groups joining the mono-
25 meric subunits. 
A further class of oligonucleotide mimetic that can be used 
for nucleic acid capture probes in several embodiments is 
cyclohexene nucleic acids (CeNA). In CeNA oligonucle-
otides, the furanose ring normally present in a DNA or RNA 
30 molecule is replaced with a cyclohexenyl ring. CeNA DMT 
protected phosphor amidite monomers have been prepared 
and used for oligomeric compound synthesis following clas-
sical phosphor amidite chemistry. Fully modified CeNA oli-
gomeric compounds and oligonucleotides having specific 
35 positions modified with CeNA have been prepared and stud-
ied (Wang et al., J.Am. Chem. Soc, 2000, 122, 8595-8602). In 
general the incorporation of CeNA monomers into a DNA 
chain increases its stability of a DNA/RNA hybrid. CeNA 
oligoadenylates formed complexes with RNA and DNA 
40 complements with similar stability to the native complexes. 
In several embodiments, a nucleic acid capture probe can 
comprise a locked nucleic acid (LNA), which can increase the 
sensitivity and specificity of conventional oligonucleotides, 
such as DNA oligonucleotides, for hybridization to short 
45 target sequences such as mature miRNAs, stem-loop precur-
sor miRNAs, pre-miRNAs, siRNAs or other non-coding 
RNAs as well as miRNA binding sites in their cognate mRNA 
targets, mRNAs, mRNA splice variants, RNA-edited 
mRNAs, antisense RNAs and small nucleolar RNAs (sn-
50 RNA). 
Locked nucleic acid (LNA) capture probes are nucleoside 
or nucleotide analogues that include at least one LNA mono-
mer (e.g., an LNA nucleoside or LNA nucleotide). LNA 
monomers are described in, for example, WO 99/14226, U.S. 
55 Pat. No. 6,043,060, U.S. Pat. No. 6,268,490, WO 01/07455, 
WO 01/00641, WO 98/39352, WO 00/56746, WO 00/56748 
and WO 00/66604. LNAs have bicyclic sugar moieties "in 
which the 2'-hydroxyl group of the ribosyl sugar ring is linked 
to the 4' carbon atom of the sugar ring thereby forming a 
60 2'-C,4'-C-oxymethylene linkage to form the bicyclic sugar 
moiety (reviewed in Elayadi et al., Curr. Opinion Invens. 
Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol, 2001, 8 
1-7; and Oram et al., Curr. Opinion Mo!. Ther., 2001, 3, 
239-243; see also U.S. Pat. Nos. 6,268,490 and 6,670,461). 
65 The synthesis and preparation of the LNA monomers 
adenine, cytosine, guanine, 5-methylcytosine, thymine and 
uracil, along with their oligomerization, and nucleic acid 
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recognition properties have been described (Koshkin et al., 
Tetrahedron, 1998, 54, 3607-3630). 
12 
70nm, 80nm, 90nm, lOOnm, 120nm, 150nm, 180nm, 200 
nm, 250 nm or 300 nm, or any number in between the afore-
mentioned sizes. In other embodiments, the nanoparticle can 
have a characteristic dimension of 10-500 nm, 10-400 nm, 
10-300 nm, 10-250 nm, 10-200 nm, 10-150 nm, 10-100 nm, 
10-75 nm, 10-50 nm, 50-500 nm, 50-400 nm, 50-300 nm, 
50-200 nm, 50-150 nm, 50-100 nm, 50-75 nm, 100-500 nm, 
100-400nm, 100-300nm, 100-250nm, 100-200nm, 100-150 
nm, 150-500 nm, 150-400 nm, 150-300 nm, 150-250 nm, 
150-200 nm, 200-500 nm, 200-400 nm, 200-300 nm, 200-250 
nm, 200-500 nm, 200-400 nm or 200-300 nm. 
In several embodiments, a particle comprises a metal par-
ticle, such as an Au, Ag, Pd, Pt, Cu, Ni, Co, Fe (e.g. iron 
sulfide), Mn, Ru, Rh, Os, or Ir particle. In various embodi-
Analogs of LNA, phosphorothioate-LNA and 2'-thio-
LNAs, have also been prepared (Kumar et al., Bioorg. Med. 
Chem. Lett., 1998, 8, 2219-2222). Preparation of locked 
nucleoside analogs containing oligodeoxyribonucleotide 
duplexes as substrates for nucleic acid polymerases has also 
been described (Wengel et al., WO 99/14226). Furthermore, 
synthesis of 2'-amino-LNA, a novel conformationally 
restricted high-affinity oligonucleotide analog has been 10 
described in the art (Singh et al., J. Org. Chem., 1998, 63, 
10035-10039). In addition, 2'-Amino- and 2'-methylamino-
LNA's have been prepared and the thermal stability of their 
duplexes with complementary RNA and DNA strands has 
been previously reported. 
In several embodiments, a nucleic acid capture probe can 
include a non-native, degenerate, or universal base such as 
inosine, xathanine, hypoxathanine, isocytosine, isoguanine, 
5-methylcytosine, 5-hydroxymethyl cytosine, 2-aminoad-
enine, 6-methyl adenine, 6-methyl guanine, 2-propyl gua- 20 
nine, 2-propyl adenine, 2-thiouracil, 2-thiothymine, 2-thio-
cytosine, 15-halouracil, 15-halocytosine, 5-propynyl uracil, 
5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo 
thymine, 5-uracil, 4-thiouracil, 8-halo adenine or guanine, 
8-amino adenine or guanine, 8-thiol adenine or guanine, 25 
8-thioalkyl adenine or guanine, 8-hydroxyl adenine or gua-
nine, 5-halo substituted uracil or cytosine, 7-methylguanine, 
7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazagua-
nine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, or 
the like. In some embodiments, a nucleic acid capture probe 30 
can include isocytosine and/or isoguanine in order to reduce 
non-specific hybridization as generally described in U.S. Pat. 
No. 5,681,702. 
15 ments, a particle comprises a metal oxide particle. Examples 
of suitable metal oxide particles include zinc oxide, titanium 
(di)oxide, iron oxide, silver oxide, copper oxide, aluminum 
oxide, or silicon ( di)oxide particles. In certain embodiments, 
In several embodiments, a nucleic acid capture probe can 
comprise an "aptamer" to bind to a nucleic acid or polypep-
tide analyte of interest. Aptamers are described in U.S. Pat. 
Nos. 5,270,163; 5,475,096; 5,567,588; 5,595,877; 5,637,459; 
5,683,867; and 5,705,337; which are herein incorporated by 
reference in their entireties. Aptamers can bind to various 
molecular targets such as small molecules, proteins, and 
nucleic acids. 
a particle comprises a magnetic particle, such as a magnetic 
bead, nanoparticle, microparticle, and the like. 
Where the analyte of interest is a nucleic acid molecule, 
several embodiments relate to methods of detecting a nucleic 
acid molecule of interest in a sample comprising: providing a 
hMRS comprising a nucleic acid capture probe associated 
with a magnetic responsive nanoparticle, wherein the capture 
probe is capable ofhybridizing to the nucleic acid molecule of 
interest to form a duplex; applying a sample for which the 
presence or absence of the nucleic acid molecule of interest is 
to be determined to the hMRS under conditions in which the 
nucleic acid molecule of interest, when present, and the cap-
ture probe sequence-specifically hybridize to form a 
duplex; and determining the presence or absence of the 
nucleic acid molecule of interest by detecting an alteration in 
a magnetic property of the hMRS or sample. In a specific 
35 example, the alteration in a magnetic property is a change in 
the magnetic resonance signal of the hMRS or the environ-
ment surrounding the hMRS. A change in the magnetic reso-
nance signal can include an increase or decrease in the T2 of 
the hMRS and/or sample. This can be further defined in 
40 relation to a negative control. In some aspects, the concentra-
tion of the nucleic acid analyte of interest in the sample is 
measured. Detecting and/or measuring the concentration of a 
nucleic acid molecule of interest in a sample can be done in 
real-time and/or in multiplex with other analytes ofinterest or 
In several embodiments, the particle associated with the 
nucleic acid capture probe comprises a nanoparticle, nano-
sphere, microcapsule, nanocapsule, microsphere, micropar-
ticle, bead, colloid, aggregate, flocculate, insoluble salt, 
emulsion, crystal, detergent, surfactant, dendrimer, copoly-
mer, block polymer, nucleic acid, carbohydrate, lipid, lipo-
some, or insoluble complex. It is contemplated that these 
types of particles can have any size in the picometer, nanom-
eter, micrometer, or millimeter range along any dimensional 
axis. As used herein, the term "nanoparticle" refers to any 
particle having a greatest dimension (e.g., diameter) that is 
less than about 2500 nm. In some embodiments, the nanopar-
ticle is a solid or a semi-solid. In some embodiments, the 
nanoparticle is generally centrosymmetric. In some embodi- 55 
ments, the nanoparticle contains a generally uniform disper-
sion of solid components. 
45 samples. 
Typically, the target analyte is isolated before being sub-
jected to hMRS. The terms "isolate", "isolated" or"isolation" 
when used with respect to the target analyte, e.g., nucleic acid 
analyte, means enriching the target analyte relative to its 
50 natural environment. Thus, enrichment could include partial 
purification or full purification, but in most cases simply 
means removing components from the crude sample. In the 
case of a blood sample, isolation might include a centrifuga-
tion step and removing a portion of the centrifuged sample. 
There are varieties of ways that the nanoparticles can be 
prepared, but typically, the result involves a nanoparticle with 
functional groups that can be used to associate the nanopar-
ticle to the binding moiety. The terms "association", "associ-
ating" or "associate" with respect to the interaction between 
Nanoparticles can have a characteristic dimension of less 
than about 1 micrometer, where the characteristic dimension 
of a particle is the diameter of a perfect sphere having the 
same volume as the particle. For example, the nanoparticle 
may have a characteristic dimension that is less than 500 nm, 
400 nm, 300 nm, 250 nm, 200 nm, 180 nm, 150 nm, 120 nm, 
100 nm, 90 nm, 80 nm, 70 nm, 60 nm, 50 nm, 40 nm, 30 nm, 
or 20 nm, or any number in between the aforementioned sizes. 
In some embodiments, the nanoparticle can have a character-
istic dimension of 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 
60 the nucleic acid capture probe and the particle generally refers 
to the adherence interaction (typically covalent binding) that 
is direct, such as directly to the material of which the particle 
is composed, or indirect, such as interaction with a coating 
(e.g. polymer coating) on the particle. Typically, association 
65 of the nucleic acid can be associated through non-polymer 
surface functionalization of the particle or via functionalized 
polymers on the particle. According to one embodiment, the 
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hMRS is a nanoparticle that is composed of a magnetic metal 
oxide and includes one or more functional groups, e.g., a 
polymer comprising one or more functional groups. When 
polymers are included, they contain functional groups that 
enable the nucleic acid to be attached to the nanoparticle to 
form the conjugate. The polymer can be a natural polymer, a 
synthetic polymer, a combination of natural and synthetic 
polymers, or derivatives of each type. The functional groups 
can be carboxy, amino, or sulfhydryl groups. In some 
embodiments, the binding moiety is attached to the nanopar- 10 
ticle through disulfide groups. The metal oxides can also be 
associated with non-polymer functional groups to form the 
nanoparticles. 
In one example, nucleic acids can be linked to the metal 
15 
oxide through covalent attachment to a functionalized poly-
merorto non-polymeric surface-functionalizedmetal oxides. 
In the latter method, the nanoparticles can be synthesized 
according to the method of Albrecht et al., Biochimie, 80 
(5-6): 379-90, 1998. Dimercapto-succinic acid is coupled to 20 
the iron oxide and provides a carboxyl functional group. By 
functionalized is meant the presence of amino or carboxyl or 
other reactive groups. 
In another example, oligonucleotides are attached to mag-
netic nanoparticles via a functionalized polymer associated 25 
with the metal oxide. In some embodiments, the polymer is 
hydrophilic. In a specific embodiment, the conjugates are 
made using oligonucleotides that have terminal amino, sulf-
hydryl, or phosphate groups, and superparamagnetic iron 
oxide nanoparticles bearing amino or carboxy groups on a 30 
hydrophilic polymer. There are several methods for synthe-
sizing carboxy and amino derivatized-nanoparticles. Meth-
ods for synthesizing functionalized, coated nanoparticles are 
discussed in further detail below. 
14 
material is known as cross-linked iron oxide or "CLIO" and 
when functionalized with amine is referred to as amine-CLIO 
or NH2 -CLIO. 
Carboxy-functionalized nanoparticles can be converted to 
amino-functionalized magnetic particles by the use of water-
soluble carbodiimides and diamines such as ethylene diamine 
or hexane diamine. 
Avidin or streptavidin can be attached to nanoparticles for 
use with a biotinylated binding moiety, such as an nucleic 
acid. See e.g., Shen et al., "Magnetically labeled secretin 
retains receptor affinity to pancreas acinar cells," Bioconjug. 
Chem., 1996, 7(3):311-6. Similarly, biotin can be attached to 
a nanoparticle for use with an avidin-labeled binding moiety. 
Another example of a polymer coating for the particle is a 
polyacrylic acid. The method of producing these is described 
further in the Examples section. 
According to an alternative embodiment, provided is a 
method to detect for the presence of antibodies in a biological 
sample. The method may include contacting the sample with 
a nanosensor that includes a nanoparticle associated with a 
binding molecule (such as a polypeptide) having an epitope to 
an antibody of interest. The term "polypeptide" as used herein 
pertains to two or more linked amino acids, and would include 
proteins. For example, if an antibody of interest is present in 
the sample, it would bind to the epitope containing polypep-
tide which would modulate the resonance signal of the sample 
and/or nano sensor. The polypeptide could pertain to a protein 
specific to a certain microorganism (such as MAP protein). If 
a subject has been exposed to a certain microorganism, the 
subject will most likely generate antibodies against that 
organism. Thus, if a change magnetic resonance signal is 
detected, then this indicates that the subject has been exposed. 
This type of assay is analogous to the classic TB skin test. 
However, instead of detect an immune reaction on the skin 
Carboxy functionalized nanoparticles can be made, for 
example, according to the method of Gorman (see WO 
00/61191). In this method, reduced carboxymethyl (CM) 
dextran is synthesized from commercial dextran. The CM-
dextran and iron salts are mixed together and are then neu-
tralized with ammonium hydroxide. The resulting carboxy 
functionalized nanoparticles can be used for coupling amino 
functionalized nucleic acids. 
35 due to the presence of antibodies, the antibody-specific 
nano sensors will detect the presence of antibodies in a sample 
through observed changes in a magnetic response. 
According to a related embodiment, provided is an anti-
body-specific nanosensor. The antibody-specific nanosensor 
40 includes a magnetically responsive nanoparticle associated 
with a molecule having an epitope to an antibody of interest. 
In a specific embodiment, the molecule having an epitope to 
an antibody of interest is a polypeptide. Carboxy-functionalized nanoparticles can also be made 
from polysaccharide coated nanoparticles by reaction with 
bromo or chloroacetic acid in strong base to attach carboxyl 45 
groups. In addition, carboxy-functionalized particles can be 
made from amino-functionalized nanoparticles by converting 
amino to carboxy groups by the use of reagents such as 
succinic anhydride or maleic anhydride. 
Nanoparticles can also be synthesized according to the 50 
methodofMolday (Molday, R. S, andD. MacKenzie, "Immu-
nospecific ferromagnetic iron-dextran reagents for the label-
ing and magnetic separation of cells," J. Immunol. Methods, 
1982, 52(3):353-67, and treated with periodate to form alde-
hyde groups. The aldehyde-containing nanoparticles can then 55 
be reacted with a diamine (e.g., ethylene diamine or hex-
anediamine ), which will form a Schiff base, followed by 
reduction with sodium borohydride or sodium cyanoborohy-
dride. 
Examples 
Design and Synthesis ofhMRS 
The detection ofMAP's 15900 genomic marker relies on 
DNA isolation and subsequent amplification and detection 
via PCR. Typically, DNA from peripheral leukocytes found in 
the buffy coat (Direct nPCR) or leukocyte-derived cultured 
bacteria (Culture-based nPCR) is first isolated in a multistep 
protocol [21], yielding bacterial DNA of high quality (FIG. 
la). However, this approach often times compromises DNA 
yield, which may impede MAP identification. In subsequent 
steps, the bacterial DNA is subjected to two 3-hour-long 
polymerase-mediated amplification rounds of the IS900 
locus, followed by gel electrophoresis. To facilitate faster 
Dextran-coated nanoparticles can be made and cross-
linked with epichlorohydrin. The addition of ammonia will 
react with epoxy groups to generate amine groups, see Hage-
mann, D., et al., Improvement of MRI probes to allow efficient 
detection of gene expression Bioconjug. Chem. 2000. 11(6): 
941-6, and Josephson et al., "High-efficiency intracellular 
magnetic labeling with novel superparamagnetic-Tat peptide 
conjugates," Bioconjug. Chem., 1999, 10(2):186-91. This 
60 detection via magnetic relaxation, a single hMRS probe was 
designed that hybridizes with the unique IS900 sequence 
within the MAP plasmid. These hMRS are composed of a 
polyacrylic acid-coated iron oxide nanoparticle onto which 
an oligonucleotide sequence (ATGTGGTTGCTGTGT (SEQ 
65 ID NO. 1 )) complementary to the IS900 sequence in MAP is 
conjugated to facilitate binding and detection. The resulting 
MAP specific hMRS had a diameter of78±3 nm, zeta paten-
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tial value of -35 mV, an average of 55 oligonucleotides per 
nanoparticle, with Rl and R2 relaxivities (at 0.47T) of 45 
mM-1 s-1 and 60 mM-1 s-1 respectively. We anticipated that 
hMRS could utilize crude DNA, obtained from isolated buffy 
coats that have been subjected to heating (FIG. la). It is well 5 
reported that heating of peripheral leukocytes accomplishes 
first the release of a pathogen from intracellular compart-
ments [21], such as phagosomes, due to extensive pore for-
mation on the host cell's plasma membrane and organelles' 
phospholipid-containing membrane. Once exposed to high 10 
temperatures, the pathogen's structural integrity is affected, 
leading to release of its genomic DNA to the aqueous milieu. 
A series of heating and cooling procedures on the isolated 
MAP DNA plasmid in the presence of hMRS reduces the 
DNA torsional strain, facilitating annealing andhydridization 15 
of the hMRS onto the IS900 region of the MAP genome (FIG. 
lb). Decreasing the sample's temperature can return the DNA 
to a higher structural order, with the hMRS still binding to the 
MAP genome and inducing increases in the sample's mag-
netic resonance signal. Specifically, the hMRS were able to 20 
bind to MAP DNA after two short heating rounds (3 min each 
at 95° C.), followed by unassisted cooling to room tempera-
ture. The fast changes in the magnetic resonance signal were 
monitored with a compact nuclear magnetic resonance instru-
ment (0.47T, Bruker, Minispec), recording increases in the 25 
sample's transverse relaxation times (li.T2+, where 
T2(sample )>T2( control)). Within 30 minutes after removing 
the samples from heat, significant and reproducible changes 
were observed prompting us to set this time-point as the 
hMRS readout point (FIG. 7). Based on the observation that 30 
the sample's T2 times were higher than those of the sterile 
control throughout the experimental time course, it was 
deduced that the hMRS first bound to the relaxed circular 
MAP DNA that was heated, while the hMRS still remained 
bound to the cooled DNA as it was returning to its supercoil 35 
form. These results were corroborated by dynamic light scat-
tering studies that showed no clustering of the nanoparticle 
suspension upon addition of the isolated MAP genome, since 
the nanoparticle diameter was found to be 81±5 nm. Likely, 
this may be attributed to the fact that during sample cooling 40 
the DNA returned to its supercoiled conformation, which can 
be in the order of a few nanometers, and as a result nominally 
altering the overall size of the hybridizing nanoparticle-DNA 
complex. 
16 
signal proximal to that of the sterile control (FIG. 2a). These 
data hint the potential use of the hMRS and magnetic relax-
ation detection for the fast and specific detection of MAP 
DNA. 
In subsequent studies, whether the hMRS could quantify 
MAP DNA was determined. MAP DNA was isolated using 
either an elaborate multistep extraction protocol to obtain 
pure DNA, or a fast 30-minute boiling-based methodology to 
obtain crude DNA. After a 30-minute incubation period, the 
hMRS were able to detect MAP DNA in both pure and crude 
DNA preparations, exhibiting concentration-dependent 
li.T2+ changes (FIGS. 2b and 2c, Table Sl). The observed 
MAP concentration response pattern exhibited a high mag-
netic resonance signal (ti. T2+) at low target concentration 
levels and low signals at higher DNA concentrations. This 
suggests that the binding between the hMRS and MAP DNA 
was facilitated via low valency interaction, as previously 
described in other models [11]. This unique interaction 
mechanism provides enhanced sensitivity during the screen-
ing of scarce biomarkers, since high signal is desired at low 
target concentrations. Quantification of the number of oligo-
nucleotides on the hMRS probe revealed that on average there 
were 55 oligonucleotides (oligos) per hMRS. This level of 
oligos per nanoparticle is in line with previous reports, where 
valency grafting of 46 oligos per nanoparticle exhibited a low 
valency binding behavior, whereas a nanoparticle with 368 
oligos obeyed a high valency mechanism [12]. A low-va-
lency-based detection approach is ideal for the identification 
of MAP in clinical samples, since it will induce a prominent 
li. T2+ signal at low numbers of MAP. Based on the findings 
that both pure and crude MAP DNA exhibited similar hMRS 
quantification patterns, it was deduced that the hMRS assay 
can detect IS900 independent of the sample's DNA extraction 
methodology. Although higher changes were recorded in 
pure MAP DNA samples, both extraction methodologies had 
equivalent detection thresholds, reaching low femtogram 
(10-15) levels. Potentially the differences in the magnitude of 
the li. T2+ from pure and crude MAP DNA might be attributed 
to the sample's unique characteristics. It is plausible that the 
high purity of the pure DNA extracts is associated with mar-
ginal protein and lipid levels, resulting in lower viscosity. 
Alternatively, a crude MAP DNA sample may have substan-
tially higher content of proteins and lipids, thus higher vis-
cosity, which may be reflected in lower li. T2+ values upon 
hMRS are Specific and Sensitive Probes 
Specificity is a critical component of any assay, supporting 
correct diagnosis and therapeutic intervention. To determine 
the specificity of the hMRS, we incubated the hMRS (6 µg 
Fe/mL) with pure DNA extracts from various mycobacteria 
and monitored changes in T2 signal. 
45 IS9000-hMRS hybridization. We then examined whether 
nested PCR (nPCR) can achieve comparable sensitivity using 
crude MAP DNA. We decided to compare our hMRS method 
with nPCR as opposed to reverse transcriptase PCR (RT-
PCR), due to the fact that MAP is an intracellular pathogen 
50 that grows very slowly. Similar to other intracellular micro-
organisms, it can be dormant and reduce its metabolism, 
suppressing transcriptional and translational activity [21]. As 
a result, the transcripts (mRNA) of even housekeeping genes 
Within 30 minutes, results indicated that only samples 
containing MAP DNA exhibited a high li. T2+ signal, being 
attributed to the hMRS-MAP DNA binding (FIG. 2a). Addi-
tionally, the hMRS were still able to identify their target in a 
solution with a mixture of MAP and other mycobacterial 55 
DNA (FIG. 2a). This indicates that the hMRS are sensitive 
and specific, without being affected by the presence of other 
mycobacterial DNA. Furthermore, addition of a synthetic 
oligonucleotide complementary to the IS900 sequence abro-
gated the signal of the hMRS upon MAP DNA addition, 60 
confirming the specificity of the hMRS probe (data not 
shown). Since other microorganisms' DNA might be found in 
a clinical sample, we examined ifthe hMRS could differen-
tiate between MAP and common Gram positive and Gram 
negative bacteria, as well as different types of mycobacteria. 65 
Results showed that only the MAP sample yielded a high 
li. T2+, whereas the other bacterial DNA samples exhibited 
are nominal and cannot be used in RT-PCR diagnostics. 
Therefore, nPCR is the technique most typically used for 
MAP detection [21]. Using nPCR, after two 3-hour-long 
cycles and electrophoresis, nPCR was not able to detect MAP 
IS900 in samples containing crude MAP DNA (FIG. 8). This 
demonstrates the sensitivity and robustness ofhMRS to rap-
idly detect their target even under conditions of interference, 
which prevent the use of traditional enzyme-based methods. 
In line with this, recent studies have demonstrated that 
nucleic-acid-decorated nanostructures can be highly stable 
even in serum-containing media and avoid non-specific pro-
tein and nuclease interactions, due to the steric inaccessibility 
and high local salt concentration introduced by the nanopar-
ticles' DNA strands [26]. Subsequently, we then compared 
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hMRS and nPCR using purified DNA extracts instead. Also identify optimal therapy [28], [29], [30]. For these studies, in 
considering the size of MAP's genome ( 4,829,781 bp) and addition to the MAP IS900 hybridizing sensor (hMRS), we 
the average molecular weight of a base pair (MW: 650), we prepared a MAP-epitope-sensing MRS ( diameter=92±4 nm, 
calculated the mass of a single MAP genome copy to be equal zeta potential=-31 mV, an average of 2 antibodies per nano-
to 5.2 fg. This value is comparable to that determined experi- 5 particle, Rl =48 mM-ls-1 and R2=57 mM-ls-1) that iden-
mentally in previous reports [27]. Hence, we accordingly tifies a conserved MAP bacterial surface antigen [31]. 
prepared serial dilutions of MAP DNA with known genome Despite their different detecting mechanisms ( oligonucle-
copy numbers. hMRS and magnetic relaxation detection otide probe vs antibody), binding site topology and target 
were able to detect a single copy of MAP DNA within 30 characteristics (DNA vs surface epitope ), both MRS provided 
minutes, whereas nPCR was able to achieve similar, although 10 a li. T2+ signal for all samples with clinical symptomology 
not as sensitive, detection (5 bacteria) only after the second (Pl-P4, FIGS. 4a and 4b ), whereas the sample from a healthy 
amplification round (FIGS. 2d and Ze, Table s2). This trans- individual (Hl, FIGS. 4a and 4b ), exhibited nominal mag-
netic signal changes. Independent confirmation of the MAP 
!ates to a total readout time for nPCR of more than 6 hours, MRS findings was achieved by performing DNA extraction 
with the need of more reagents, such as primers and enzymes, and nPCR analysis. In addition, we used both the hMRS and 
as well as labor and equipment time. Intriguingly though, the 
15 
epitope MRS to screen for the presence of MAP in tissue 
hMRS had a single genome-copy detection threshold when samples from cattle infected with Johne's disease. Since 
crude MAP DNA was used, without compromising their sen- MAP causes Johne's disease in cattle, we investigated if these 
sitivity in this minimally processed sample (FIG. 9). Overall, probes can identify this intracellular pathogen at the genomic 
these data demonstrate that hMRS can achieve fast single and epitope levels in homogenized tissue samples. Results 
MAP genome detection even in crude DNA samples, outper- 20 showed significant magnetic signal changes in all tissues 
forming nPCR in readout time, sensitivity and robustness. from infected animals (FIGS. 4c and 4d), demonstrating that 
hMRS Achieve Genome-Based Detection of the Intracellular hMRS and epitope MRS can quickly detect MAP in clinically 
Pathogen Mycobacterium avium Spp. Paratuberculosis in relevant samples at both the genomic and epitope levels. It is 
Cultured Clinical Isolates and Tissue Samples interesting to note that in both human biopsies from Crohn's 
Since the hMRS detected MAP DNA in samples from pure 25 patients and tissues from animals with Johne' s disease, the 
bacterial cultures, we investigated if the nanosensors could magnetic relaxation signal obtained with the hMRS probe 
identify their targets in more complex samples, such as cul- correlates with that obtained with the epitope-sensing MRS 
tured clinical isolates and homogenized tissue preparations. for the same sample. The differences in the li. T2+ among the 
We first screened cultures of clinical isolates from Crohn's animal tissue samples might be attributed to the fact that the 
disease patients with the hMRS and compared these results 30 spatial concentration of MAP differs among the various tis-
with nPCR. Specifically, we used crude DNA for the hMRS sues within the same animal due to Johne's disease patho-
and pure DNA for the nPCR, since nPCR cannot utilize crude physiology. Overall, these results indicate that these probes 
DNA. Following a single-step procedure, crude DNA can be used for the screening of complex tissue samples with 
obtained from cultured isolates of healthy individuals yielded minimal or no sample preparation, supporting clinical deci-
a magnetic signal change that was comparable to that of the 35 sion making. 
sterile culture medium (ti. T2+= 1.3±0.2 ms), establishing this hMRS Quickly Detect MAP DNA in Peripheral Blood 
magnetic signal change as the hMRS negative control base- Acknowledging previous reports that identified MAP in 
line. Further studies indicated that the hMRS were able to the blood of Crohn's disease patients, we sought to screen 
rapidly detect MAP in several clinical isolates with good blood samples from healthy individuals and Crohn's disease 
correlation to the culture-based nPCR, indicating that the patients for the presence ofIS900 (n=34). For this, we chose 
hMRS can quickly detect the IS900 biomarker in minimally 40 to screen MAP' s IS900 genomic marker, rather than a protein 
processed cultured clinical isolates (FIG. 3, Table S3). Out of ( epitope) marker, since the later involves the use of anti-MAP 
the ten cultures screened, one sample from a culture of an ilea! antibodies that are difficult to reproducibly generate while 
biopsy (GN2') was identified as positive by the hMRS, yet avoiding antibody batch variabilities. In addition, a DNA-
negative by nPCR. A false negative result with culturing based hybridizing MRS would be more robust and selective 
methods can occur when either low amounts of the pathogen 45 than an antibody-based MRS. Peripheral blood was collected 
are present in the collected sample or when the pathogen is and DNA was directly isolated from white blood cells, via 
not viable to properly grow in culture. This prompted us to either a 30-minutes crude DNA extraction protocol for hMRS 
analyze the culture sample from the corresponding patient's or a multistep high purity and quality DNA isolation proce-
blood (GN2). We reasoned that viable MAP could be present dure for direct nPCR screening. Direct nPCR for the MAP 
in the patient's leucocytes, granting correct diagnosis. 50 IS900 biomarker provided conclusive results about the patho-
Indeed, culture from the blood sample GN2 was identified as gen' s presence in these samples, hence these samples estab-
positive in agreement with the hMRS diagnosis and clinical lished the first peripheral blood cohort (Cohort 1). In this 
sympthology. Therefore, nPCR may have failed to detect cohort, positive samples were defined as those samples where 
IS900 in ilea! biopsy GN2' perhaps due to either low levels of a prominent band corresponding to IS900 was observed and 
the pathogen or the presence of interferences in the biopsy 
55 
negative samples were those where no visible band was 
sample that inhibited growth of the pathogen in culture. Over- observed at all. Control and Cohort 1 samples were screened 
all, these results suggest that the high sensitivity of hMRS with hMRS, after a 30-minutes crude DNA extraction proto-
facilitates the positive identification of MAP in blood and col from white blood cells. Crude DNA extracted from con-
biopsy samples, whereas PCR techniques were not always trol samples induced small changes in the magnetic signal 
successful in identifying MAP. (li.T2+=1.3±0.1 ms), which served as the hMRS reference 
Next, we screened various ilea! biopsies from Crohn's 60 point. Interestingly, results obtained with hMRS and mag-
disease patients for the presence of MAP at the genomic and netic relaxation detection using crude DNA samples from 
epitope levels using magnetic relaxation. We performed these patients within Cohort 1 were in complete agreement with 
studies since clinical diagnostics frequently require the iden- results obtained with direct nPCR that used pure DNA 
tification of a biomarker at multiple levels. For instance, the samples (FIG. 5, Table S4). Addition of a synthetic target 
aberrant activity of an oncogene has to be evaluated at the 65 complementary to hMRS led to signal abrogation in the 
transcriptional, translational and post-translational levels, in samples that had been identified as MAP positive, confirming 
order to understand causality, delineate disease dynamics and the specificity of the assay. This indicates that the hMRS can 
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detect their target in minimally processed blood samples, 
while eliminating lengthy sample preparation procedures. 
Next, a second cohort of blood samples (Cohort 2, Table 1) 
was represented by samples where direct nPCR analysis pro-
vided dubious results. In samples within this cohort, classifi-
cation as either positive or negative was not possible due to 
the presence of smeared or faint bands. The presence of these 
dubious samples, either false-positives or false-negatives, is a 
major problem with current nPCR techniques. Therefore, we 
examined if the hMRS performs better than direct nPCR and 1 o 
culture-basednPCR in determining if an individual is positive 
or negative based on his/her clinical state (in this case being 
Crohn's positive or healthy). For the culture-based nPCR, 
inoculants from white blood cells were incubated for 12 
weeks in specialized mycobacterial media (n=26), allowing 15 
the potential growth of any viable MAP bacteria. After this 
long incubation period, pure DNA extraction was performed, 
followed by nPCR analysis. Interestingly, the culture-based 
nPCR was better in predicting disease than direct nPCR, 
which was performed on pure DNA extracted from white 
20 
blood cells readily after venipuncture (blood draw) (FIGS. 6a 
and 6b). This may be attributed to the ability of bacterial 
culturing to provide more high-quality MAP DNA, as 
opposed to DNA directly obtained from white blood cells. 
Additionally, it is plausible that culturing can facilitate 
growth of even low populations of bacteria in optimal condi- 25 
tions, whereas direct pure DNA isolation from white blood 
cells may result in low genome recoveries of rare bacteria 
throughout its multiple steps and presence of interferences, 
like nucleases, cytosolic proteins and membrane lipids. Com-
paring both PCR setups with the crude DNA hMRS method- 30 
ology, we found that the nanoparticle-based method outper-
formed both PCR-based methods in correlating MAP's 
presence and disease state (FIGS. 6a and 6b). This hints the 
hMRS' sensitivity, and the ability of the crude DNA extrac-
tion method to provide adequate DNA levels that are suffi- 35 
cient to facilitate improved bacterial detection. Furthermore, 
a receiver operating characteristic (ROC) analysis based on 
hMRS-mediated MAP quantification indicated that hMRS 
can provide improved clinical diagnosis than the qualitative 
(positive vs negative) nested PCR assays (FIG. 6a, Table 1). 
40 
Specifically, hMRS were able to better correlate bacterial 
biomarker presence and Crohn' s disease symptomology than 
both direct and culture-basednPCR. This suggests the poten-
tial use of hMRS for the future investigation of complex 
disease and the role of various disease effectors and contribu-
tors, to better understand pathogenesis' mechanisms and its 45 
dynamic interactions. Taken together, this data prove that 
hMRS can rapidly detect a unique nucleic acid signature of an 
intracellular pathogen in clinical samples with improved 
fidelity and higher sensitivity than PCR. This enhanced detec-
tion translates into a more sensitive pathogen detection and so 
more accurate diagnosis of the disease, providing important 
clinical information for successful treatment and therapeutic 
interventions due to early diagnosis. 
20 
TABLE I-continued 
Clinical data and hMRS results of minimally 
processed blood samples (Cohort 2) 
hMRS 
Age Culture- MAP 
Sam- (years)/ Diag- Direct based L\.T2 (bac-
ple sex no sis PCR PCR MAP (ms) teria) 
BS M/56 CD + + (3/3) 7.6 12826 
B6 F/57 Healthy + + (3/3) 4.2 465264 
B7 M/28 CD + + (3/3) 7.5 13963 
BS F/31 Healthy + + (3/3) 7.0 24006 
B9 M/18 CD + + (3/3) 10.3 760 
BIO M/28 CD + + (3/3) 5.2 162513 
Bll F/16 CD + + (3/3) 4.4 400959 
B12 F/24 Healthy + - (0/3) 0.2 0 
B13 F/61 Healthy + - (0/3) 0.4 0 
B14 M/65 Healthy + - (0/3) 0.1 0 
B15 F/62 Healthy + - (0/3) 0.1 0 
B16 F/23 CD + - (0/3) 0.7 0 
B17 F/48 Healthy + - (0/3) 0.6 0 
B18 M/19 CD + - (0/3) 0.0 0 
B19 F/26 Healthy + - (0/3) 0.4 0 
B20 M/43 CD + - (0/3) 0.0 0 
B21 F/50 CD + - (0/3) 0.1 0 
B22 F/12 Healthy + + - (0/3) 0.5 0 
B23 M/57 Healthy + + - (0/3) 0.0 0 
B24 F/23 Healthy + + - (0/3) 0.6 0 
B25 M/61 Healthy + + - (0/3) 0.2 0 
B26 F/49 Healthy + + - (0/3) 0.3 0 
Discussion 
One of the aims of the studies in this Example was to 
develop and test a nanoparticle-based assay for the sensitive 
detection of genomic bacterial biomarkers of an intracellular 
pathogen in clinical samples. Preliminary studies demon-
strated that the hMRS can specifically detect a conserved 
genomic element (IS900) in MAP' s genome, and not in other 
microorganisms. Through additional studies, it has been 
identified that the sensitivity of the nanosensors was equal to 
one genome copy even in minimally processed samples, 
allowing detection of MAP in clinical isolates, tissue homo-
genates and blood. Compared to nPCR, hMRS had improved 
performance and yielded faster results. Consequently, this 
translates to lower costs, since the magnetic nanosensors are 
fairly easy and cheap to manufacture in larger quantities, and 
the assay does not require multiple oligonucleotide primer 
pairs, expensive enzymes and nucleotides. Detection was 
performed using a simple table-top relaxometer that mea-
sured the increase in the water proton relaxation time (NMR 
signal) that occurred after the hMRS probes bound to their 
genomic target. The unprecedented detection limit of this 
technique is due to the build-in water relaxation amplification 
that results upon a single binding event. The T2 relaxation 
times ofhundreds of thousands of water molecules surround-
ing the hMRS probes increase upon binding of a single probe 
TABLE 1 
Clinical data and hMRS results of minimally 
processed blood samples (Cohort 2) 
55 to the target. This is also facilitated by the low valency of the 
hMRS probe that induces drastic changes at low concentra-
tion of the target, or in this case low copy numbers of the 
genomic target. This approach contrasts with previous mag-
Age 
Sam- (years)/ Diag- Direct 
ple sex nos is PCR 
Bl F/51 CD 
B2 F/27 CD 
B3 F/73 Healthy 




PCR MAP (ms) 
+ + (3/3) 8.4 
+ + (3/3) 8.6 
+ + (3/3) 9.1 










netic relaxation approaches that rely on the use of two mag-
netic nanoparticle probes that hybridize to adjacent 
sequences on a DNA target, facilitating clustering of the 
nanoparticles with a corresponding decrease in the T2 relax-
ation times [32], [33]. Since our approach does not rely on 
nanoparticle clustering and only the binding of the nanopar-
ticle is sufficient for detection, a faster, more sensitive mag-
netic relaxation assay that rivals PCR has been developed for 
the screening of an intracellular pathogen genomic marker. 
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Apart from a table-top relaxometer, portable magnetic relax- the state of the disease, correlating the clinical state of a 
ometers have been developed, suitable for point-of-care patient with the presence of MAP in blood samples (FIG. 6). 
screening with hMRS [34]. The use ofhMRS could be a powerful new tool in the study of 
hMRS can be used for the detection of diverse targets in the mechanism of infection of intracellular pathogens and its 
complex media, including turbid and opaque clinical samples 5 relation to disease state, as well as in elucidating intracellular 
[11], [12]. Herein, our results demonstrate that the hMRS pathogens' adaptation strategies [38]. Difficulties in detect-
binding can achieve the unprecedented and fast detection of a ing MAP hamper studies aimed at the investigation of the 
single genome copy of an intracellular pathogen. This is potential role of MAP in Crohn's disease pathology, as well 
critical for the identification of extremely virulent pathogens. as the pathogen's impact on the dairy and beefindustries [39]. 
As MAP is an intracellular pathogen similar to M. tubercu- 10 Overall, these studies provide evidence for the use ofhybrid-
losis, its detection is difficult, due to the pathogen's residence 
izing magnetic nanosensors and magnetic relaxation detec-
within an infected leukocyte's organelles. Thus contempo-
tion to reliably identify the presence of an intracellular patho-rary diagnostic methodologies rely on cell isolation, cell lysis 
and nucleic acid isolation, in order to yield high purity DNA. gen in clinical samples in a fast, cost-effective and highly 
This renders MAP's detection problematic since the micro- 15 sensitive way. 
organism has to be isolated from highly complex samples, Methods 
such as blood or severely inflamed tissue biopsies, before Preparation ofIS900-Specific hMRS 
amplification and detection via PCR analysis. Apart from The IS900-specific hMRS were prepared from propargy-
DNA quality, the quantity of MAP DNA can affect the out- lated polyacrylic-acid-coated iron oxide nanoparticles, utiliz-
come of PCR. For instance, low MAP DNA levels from a 20 ing literature available protocols [11]. Specifically, incorpo-
clinical sample may not be successfully amplified through ration of propargyl groups on polyacrylic-acid-coated iron 
direct nPCR or biological matrix components can affect the oxide nanoparticles was achieved via the carbodiimide chem-
polymerase activity, yielding false-negative or dubious istry, followed by magnetic separation of the nanoparticles, 
results. In our studies, a significant number of samples that using an LS25 MACS column (Miltenyi) [11 ]. Subsequently, 
were identified as MAP dubious by direct nPCR were found 25 the propargyl-functionalized iron oxide nanoparticles were 
to be positive by culture-based nPCR and hMRS (Cohort 2), reacted with an azide-modified oligonucleotide, which is 
indicating that the pathogen was originally present in the complementary to a segment ofMAP's IS900 genomic ele-
patient' s blood (albeit in low amounts) and successfully grew ment. Conjugation of the azide-terminated 15-bp oligonucle-
in culture at adequate levels. otide 5'-ATGTGGTTGCTGTGT-3' (SEQ ID NO. 1) was 
The culture-basednPCR, relies on the availability of viable 30 achieved via "click" chemistry, as previously described [ 40]. 
bacteria in the clinical sample that can be grown in culture in Bn"efly 400 µL propargylated 1·ron oxi"de nanoparti"cles were 
' sufficient amounts before nPCR. Most clinical microbial resuspended in 1,100 µL NaHC03 buffer (0.1 M, pH 8.4). To 
diagnostics rely on the growth of the pathogen in culture, 
before performing the appropriate immunological or PCR this, 200 µL ofl 0 mM TCEP (tris(2-carboxyethyl)phosphane 
tests [35], [36]. Growth can be observed within 12 to 24 hours 35 hydrochloride, Sigma) were added as a reducing agent. 
for fast-growing microorganisms, but for slow-growing intra- Twenty µL of 6.3 M oligo were diluted in 80 µL NaHC03 
cellular microorganisms like MAP it can take from a week up buffer (0.1 M, pH 8.4) and added to the nanoparticle solution. 
to several months.Anotherproblem with this technique is that The reaction was initiated with the dropwise addition of 150 
some microorganisms are difficult to culture in the laboratory, µL Cu(I)-TBTA complex (tris(benzyltriazolylmethyl)amine, 
which limits their detection. Although highly reliable, cul- 40 10 mM, Sigma), which was previously prepared in DI water 
ture-based PCR can result in the identification of samples as and tbutanol (9[ratio] 1 ). The reaction was incubated at room 
false-negative, due to the absence of a viable pathogen or the temperature under continuous mixing for 3 hours, followed 
inability of the pathogen to grow in culture. Therefore, it is by overnight incubation at 4 ° C. under constant mixing. The 
plausible that samples that might be found to be positive by resulting IS900 hMRS were dialyzed against DI water using 
direct nPCR and hMRS to be identified as negative 12 weeks 45 a 6,000-8,000 MWCO membrane (Spectrum), followed by 
after by culture-based nPCR. This is common for low bacte- magnetic separation with an LS25 MACS column (Miltenyi). 
rial loads of slow-growing microorganisms that require The epitope-sensing MRS were formulated as previously 
highly specialized media and cultural conditions, whose reported, and the MAP antibody was obtained from Dr. Nas-
inadequacy might drastically affect bacterial viability leading er' s lab [12]. Briefly, polyacrylic-acid-coated iron oxide 
to cell death and DNA degradation [3 7]. These problems in 50 nanoparticles were conjugated to Protein G via the EDC/NHS 
detection with PCR methods are encountered in the detection chemistry, in order to have Protein Gas a high-affinity immu-
of any intracellular pathogen, as the pathogen has optimized noglobulin linker that provides optimal antibody orientation 
its adaptation and growth within a host cell. Due to their [12]. The reaction was performed according to the literature, 
sensitivity and minimal sample processing, hMRS are followed by magnetic separation through a lx-PBS-equili-
capable of circumventing PCR's obstacles and achieving 55 brated LS25 column and antibody conjugation [12]. The 
improved clinical diagnosis. Our findings indicate that hMRS nanoparticle valency of the antibody-carrying nanoparticles 
can detect an intracellular pathogen's genomic marker in was assessed through quantification of the nanoparticles' pro-
biological fluids (i.e. blood) and tissue homogenates within tein content, using published methodologies [ 11]. Size deter-
one hour, where the first 30 minutes are spent on crude DNA mination of all hMRS was achieved through dynamic light 
extraction and the remaining time on readout. 60 scattering, using the PDDLS Coo!Batch 40T instrument and 
Herein, we have also demonstrated that MAP DNA can be Precision Deconvolve 32 software. Zeta potential measure-
detected in various tissues from Johne's disease animals, as ments were performed on a Malvern zetasizer, while the Rl 
well as in biopsies and blood from Crohn' s disease patients, at and R2 relaxivities were determined after determination of 
the epitope and genomic biomarker levels. Furthermore, our 
results indicate that hMRS can detect the presence of MAP in 65 
Crohn' s disease patients more reliably than direct or cultured-
based nPCR. As a matter of fact, hMRS is a better predictor of 
the nanoparticle's iron content and relaxation studies on a 
compact relaxometer (Minispec, Bruker). Determination of 
the hMRS oligonucleotide concentration was achieved by 
monitoring the absorbance at 260 and 305 nm (background), 
US 9, 109,249 B2 
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using a Nanodrop 1000 spectrophotometer (Thermo Scien-
tific), as previously described [12]. The hMRS were stored at 
4 ° C. until further use. 
Bacterial Cultures, Isolates and Homogenized Tissue 
24 
quantified as described in the preceding section (DNA extrac-
tion methodology). Nested PCR (nPCR) was performed as 
previously described [21]. 
Blood Samples, Extraction of Bacterial DNA from White 
Blood Cells and MAP Culturing Lab strains of MAP and clinical isolates were grown in 5 
12B* BACTEC bottles (Becton Dickinson) as previously 
described [21]. Quantification of MAP grown in the 
BACTEC bottles was assessed with the BACTEC 460 TB 
Analyzer (Becton Dickinson). Heat-inactivation of MAP was 
performed by autoclaving the BACTEC bottle for 10 mins. 
Proteus vulgaris #8427, Staphylococcus aureus #33862, 
Pseudomonas aeruginosa #27853, Enterococcus faecalis, 
Escherichia coli #8739, and Serratia marcensis were grown 
in culture tubes with nutrient broth, and bacterial growth was 
monitored spectrophotometrically. Heat inactivation of these 
bacteria was performed by autoclaving the culture tubes for 
10 minutes. Upon inactivation, all bacterial stocks were 
placed in a Fisher Isotemp freezer (Fisher Scientific), until 
further use. Clinical isolates and tissue specimens from ani-
mals with Johne's disease were obtained from tissue collec-
tions stored in Dr. Naser's laboratory. 
Blood samples were collected from healthy individuals 
and patients with Crohn's disease atthe University of Florida, 
College of Medicine, in accordance to Institutional Review 
Board guidelines. The samples were coded and sent to the 
University of Central Florida for blind screening via PCR and 
10 
hMRS analyses, without knowing in advance the individual's 
condition, demographics andMAP's presence (Cohorts 1 and 
2). Isolation of white blood cells was achieved via centrifu-
gation at 3,000 rpm for 10 minutes at room temperature, as 
previously described [21]. Pure DNA was extracted via phe-
15 nol/chloroform/isoamyl alcohol precipitation, similar to pre-
viously published methodologies. The pure DNA was sub-
jected to direct nested PCR, as described above. Crude DNA 
extraction from the isolated white blood cells was achieved 
via centrifugation at 13,200 rpm for 2 minutes. The resulting 
Extraction of Pure and Crude Bacterial DNA from Bacterial 
Cultures 
20 pellets were resuspended in 120 µL sterile TE buffer (10 mM 
Tris, 1 mM EDTA, pH 8.0) and incubated in a dry heat bath at 
100° C. for 30 minutes, followed by cooling and centrifuga-
tion at 12,000 rpm that provided us with supematants rich in 
crude DNA. For bacterial culturing, buffy coat samples were DNA was extracted from cultured bacteria in a class II 
biosafety cabinet, according to literature-available proce-
dures [21]. One mL of bacterial cultures was aseptically 
transferred to microcentrifuge tubes, followed by centrifuga-
tion at 13,200 rpm. The resulting pellets were resuspended in 
120 µL sterile TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) 
and incubated in a dry heat bath at 100° C. Samples without 30 
further processing were used as crude DNA extracts in MRnS 
and nPCR studies. In order to obtain pure bacterial DNA, 
after heating the samples, we placed them on ice for 15 
minutes and then centrifuged them at 12,000 rpm for 10 
minutes at 4° C. The supernatants were transferred to Phase- 35 
lock gel tubes (Eppendorf), which were supplemented with 
200 µL of phenol/chloroform/isoamyl alcohol (1: 1:24 v:v, 
Acros). The tubes were centrifuged for 5 minutes (12,000 
rpm, 4 ° C.), and the supernatants were precipitated using 400 
25 prepared in sterile phosphate buffered saline as described 
before and inoculated on MGIT bottles. The inoculants were 
first incubated at 37° C. in a 5% C02 atmosphere for 12 
weeks, and then pure DNA extraction was performed as 
µL 100% ethanol cooled to -20° C. The precipitated DNA 40 
was washed, dried, and finally reconstituted in 50 µL TE 
buffer. Pure and crude bacterial DNA was stored at 4 ° C. until 
further analysis, whereas spectrophotometric quantification 
of DNA content was achieved using a compact spectropho-
tometer (Nanodrop 1000, Thermo Scientific). Crude and pure 45 
DNA extractions from clinical isolates were similarly per-
formed. 
hMRS and Nested PCR Experiments 
Serial dilutions of bacterial DNA were prepared in TE 
buffer. For the relaxation-mediated experiments, 200 µL of 50 
the nanoparticle suspension (6 µg Fe/mL in 0.1 M phosphate 
buffer, 0.1 M NaCl, pH 7.4) were incubated with 1 µL of 
bacterial DNA or control (TE buffer). The samples were 
heated twice for 3 minutes at 95° C. After this, the samples 
were transferred to relaxometer tubes and cooled down at 55 
room temperature, while taking relaxation measurements on 
a magnetic relaxometer (Mini spec, Bruker). For the specific-
ity assays using a complementary synthetic target (5'-TCCT-
TCGGCCATCCAACACAGCAACCACAT-3' (SEQ ID NO. 
stated above. 
Measurement of Proton Relaxation Times 
Spin-spin relaxation times (T2) were measured using a 
0.47 T mq20 NMR analyzer (Minispec, Bruker). T2 values 
were obtained before and after addition of the sample, and 
through the time course of the study. All T2 measurements 
were performed using a CPMG pulse-echo train with a 1.5 ms 
interpulse spacing (Bruker Corp., Billerica, Mass.). The 
change in magnetic resonance signal (ti. T2+) was defined as 
the sample's T2 minus the magnetic signal of the correspond-
ing negative control. All experiments and measurements were 
carried out in triplicate and data were expressed as 
mean±standard error, unless otherwise denoted. 
Statistical Analysis 
Clinical diagnosis and sample collection was performed at 
the College of Medicine, University of Florida, based on 
clinical and endoscopic criteria [21]. Samples identified as 
IS900-positive by the hMRS method had an average li.T2+ 
higherthan 1.5 ms, while positive samples bythenestedPCR 
method had a unique 298-bp nucleotide sequence. The aver-
ages of three independent experiments are reported, unless 
otherwise stated. Two-proportion z-test statistics were deter-
mined through the SPSS package, with the confidence level 
set at 95% (IBM Co.). ROC analysis was performed based on 
hMRS determination of the sample's MAP load. This was 
achieved through the correlation of the li. T2+ signal to bac-
terial genome copies, using a crude extracted DNA standard 
curve (FIG. 9). For nPCR, the presence of a band correspond-
ing to IS900 was marked as positive (value=!), whereas its 
absence was assigned as negative (value=O). The overall ROC 
methodology was performed as previously reported in litera-
60 ture [34]. Specifically, the classification variable was the indi-
vidual's clinical condition (Crohn's disease vs healthy), 
whereas the output curve was fitted using logistic regression. 
2), 1 µL of the target (1.1 M) was added to the hMRS myco-
bacterial samples containing the same DNA concentration 
(3.5 ng/µL). Similar DNA concentration was used for the 
specificity experiment utilizing other Gram-positive and 
Gram-negative bacteria and hMRS (3 µg Fe/mL). For the 
sensitivity experiments, serial dilutions of pure and crude 65 
MAP DNA were prepared from pure cultures of MAP grown 
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<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 15 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
28 
<223> OTHER INFORMATION, synthetic construct; azide modified 
oligonucleotide 
<400> SEQUENCE, 1 
atgtggttgc tgtgt 
<210> SEQ ID NO 2 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
15 
<223> OTHER INFORMATION, synthetic construct; oligonucleotide 
<400> SEQUENCE, 2 
tccttcggcc atccaacaca gcaaccacat 
The invention claimed is: 
. 1. A method of detecting a nucleic acid analyte of interest 
m a sample, the method comprising: 
(a). contacting. nucleic ~cid from a sample with a hybridiz- 30 
mg magnetic relaxat10nnanosensor (hMRS) comprising 
a plu.rality of nucl.ei~ acid sequence probes configured to 
specifically hybnd1ze to one unique sequence of the 
nucleic acid analyte of interest, so that only one hMRS 
hybridizes per nucleic acid analyte of interest; and 
(b) detecting a change in the magnetic resonance signal 
35 
from a hMRS hybridized to a nucleic acid analyte of 
interest in the nucleic acid from the sample; thereby 
detecting the presence of the nucleic acid analyte of 
interest in the sample. 
2. The method of claim 1, further comprising the step of 
40 
isolating nucleic acid from the sample to obtain isolated 
nucleic acid. 
.3. The method of claim 2, wherein said contacting nucleic 
acid from the sample comprises contacting isolated nucleic 
acid with at least one hMRS. 45 
4. The method of claim 1, wherein said sample is any 
sample harboring microorganisms from clinical or environ-
mental sources. 
5. The method of claim 1, wherein the nucleic acid analyte 
of interest is of a microorganism. 50 
6. The method of claim 5, wherein the microorganism is a 
strain of bacteria. 
7. The method of claim 6, wherein the bacteria is a Myco-
bacterium, and wherein the Mycobacterium is Mycobacte-
rium avium spp. Paratuberculosis. 
30 
8. The method of claim 5, wherein said nucleic acid analyte 
of interest is DNA or RNA sequence of a microorganism. 
9. The method of claim 8, wherein said nucleic acid analyte 
of interest is IS900 nucleotide sequence specific to MAP. 
10. The method of claim 1, wherein said hMRS comprises 
a magnetic nanoparticle. 
11. The method of claim 10, wherein said magnetic nano-
particle comprises a metal or metal oxide. 
12. The method of claim 1, wherein said method can detect 
the presence of a nucleic acid analyte of interest within 90 
minutes or less. 
13. A hybridizing magnetic relaxation nanosensor 
(hMRS), comprising a magnetic nanoparticle associated with 
a pl~r~lity of nucle.ic acid probes configured to specifically 
~ybnd1ze to one umque sequence of a nucleic acid analyte of 
mterest, so that only one hMRS hybridizes per nucleic acid 
analyte of interest. 
14. The hMRS of claim 13, wherein said magnetic nano-
particle comprises a metal or metal oxide. 
15. The hMRS of claim 13, wherein said magnetic nano-
particle comprises iron oxide. 
16. The hMRS of claim 13, wherein said nucleic acid 
analyte of interest is of a microorganism. 
17. The hMRS of claim 16, wherein said microorganism is 
a strain of bacteria. 
18. The hMRS of claim 17, wherein said bacteria is a 
Mycobacterium, and wherein said Mycobacterium is Myco-
bacterium avium spp. Paratuberculosis. 
* * * * * 
